Depression can be viewed as a network of depressive symptoms that tend to reinforce each other via feedback loops. Specific symptoms of depression may be differently responsive to antidepressant treatment, and some symptoms may be more important than others in the overall improvement of depression associated with treatment. We pooled prospective data from eight industry-sponsored placebo-controlled trials for paroxetine, fluoxetine and imipramine (total n = 3559) to examine whether improvements in specific depressive symptoms were more strongly related to improvements in other depressive symptoms among patients on active antidepressant treatment as compared to placebo. Depressive symptoms were assessed with the 17-item Hamilton Depression Rating Scale. Data on treatment was dichotomized into active treatment (receiving any antidepressant agent) vs. placebo. Time-lagged longitudinal analyses suggested that improvement in three symptoms—depressed mood, insomnia, and suicidality—had a broader overall impact on subsequent improvement in other depressive symptoms in the antidepressant condition compared to placebo (i.e., greater out-strength). Moreover, improvements in depressed mood and insomnia were more likely to follow the improvements in other symptoms in the antidepressant condition compared to placebo (i.e., greater in-strength). These results from clinical trial data suggest that depressed mood, insomnia, and suicidality may be particularly important in accounting for the remission and recovery in response to antidepressant treatment.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fried EI, van Borkulo CD, Cramer AOJ, Boschloo L, Schoevers RA, Borsboom D. Mental disorders as networks of problems: a review of recent insights. Soc Psychiatry Psychiatr Epidemiol. 2017;52:1–10.
Cramer AOJ, Waldorp LJ, Van Der Maas HLJ, Borsboom D. Comorbidity: a network perspective. Behav Brain Sci. 2010;33:137–50.
Bringmann LF, Lemmens LHJM, Huibers MJH, Borsboom D, Tuerlinckx F. Revealing the dynamic network structure of the Beck depression inventory-II. Psychol Med. 2015;45:747–57.
Airaksinen J, Gluschkoff K, Kivimäki M, Jokela M. Connectivity of depression symptoms before and after diagnosis of a chronic disease: a network analysis in the U.S. health and retirement study. J Affect Disord. 2020;266:230–4.
Hakulinen C, Fried EI, Pulkki-Råback L, Virtanen M, Suvisaari J, Elovainio M. Network structure of depression symptomology in participants with and without depressive disorder: the population-based Health 2000–2011 study. Soc Psychiatry Psychiatr Epidemiol. 2020. https://doi.org/10.1007/s00127-020-01843-7.
Bos FM, Fried EI, Hollon SD, Bringmann LF, Dimidjian S, DeRubeis RJ, et al. Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment. Soc Psychiatry Psychiatr Epidemiol. 2018;53:617–27.
van Borkulo C, Boschloo L, Borsboom D, Penninx BWJH, Waldorp LJ, Schoevers RA. Association of symptom network structure with the course of depression. JAMA Psychiatry. 2015;72:1219–26.
Groen RN, Snippe E, Bringmann LF, Simons CJP, Hartmann JA, Bos EH, et al. Capturing the risk of persisting depressive symptoms: A dynamic network investigation of patients’ daily symptom experiences. Psychiatry Res. 2019;271:640–8.
Fried EI, Nesse RM. Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential. BMC Med. 2015;13:72.
Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016;21:523–30.
Hieronymus F, Nilsson S, Eriksson E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6:e834.
Blanken TF, Van Der Zweerde T, Van Straten A, Van Someren EJW, Borsboom D, Lancee J. Introducing network intervention analysis to investigate sequential, symptom-specific treatment effects: a demonstration in co-occurring insomnia and depression. Psychother Psychosom. 2019;88:52–4.
World Health Organization. ICD-10: International statistical classification of diseases and related health problems: tenth revision, 2nd edn. World Health Organization; 2004.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Association; 2013.
Serafini G. Neuroplasticity and major depression, the role of modern antidepressant drugs. World J Psychiatry. 2012;2:49–57.
Dew MA, Reynolds CF, Houck PR, Hall M, Buysse DJ, Frank E, et al. Temporal profiles of the course of depression during treatment predictors. Arch Gen Pyschiatry. 1997;54:1016–24.
Pigeon WR, Hegel M, Unützer J, Fan M-Y, Sateia MJ, Lyness JM, et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep. 2008;31:481–8.
Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19:63.
Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD010753.pub2.
García-Velázquez R, Jokela M, Rosenström TH. Direction of dependence between specific symptoms of depression: a non-gaussian approach. Clin Psychol Sci. 2019;8:240–51.
Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993;8:186–212.
Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790–2.
Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry. 2000;57:311.
Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41–7.
Schistermann EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488–95.
Bringmann LF, Elmer T, Epskamp S, Krause RW, Schoch D, Wichers M, et al. What do centrality measures measure in psychological networks? J Abnorm Psychol. 2019;128:892–903.
Fisher AJ, Reeves JW, Lawyer G, Medaglia JD, Rubel JA. Exploring the idiographic dynamics of mood and anxiety via network analysis. J Abnorm Psychol. 2017;126:1044–56.
Fisher AJ, Medaglia JD, Jeronimus BF. Lack of group-to-individual generalizability is a threat to human subjects research. Proc Natl Acad Sci. 2018;115:E6106–15.
Molenaar PCM. On the implications of the classical ergodic theorems: analysis of developmental processes has to focus on intra-individual variation. Dev Psychobiol. 2008;50:60–9.
We thank GSK for kindly providing us with data from the included trials, and www.clinicalstudydatarequest.com for enabling access to the data. This study was supported by the Academy of Finland (grant numbers 311578 and 329224).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Komulainen, K., Airaksinen, J., Savelieva, K. et al. Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials. Mol Psychiatry 26, 3328–3335 (2021). https://doi.org/10.1038/s41380-020-00884-3
Molecular Psychiatry (2021)